Skip to main content
Premium Trial:

Request an Annual Quote

For Future Pandemics

The UK is launching a new health agency aimed at preventing and responding to future pandemics, the Guardian reports.

The agency, called the UK Health Security Agency, is to be led by Jenny Harries, the deputy chief medical officer for England, it adds. Harries previously served on the Joint Committee for Vaccination and Immunization. The Guardian further notes that UKHSA, which is to formally launch at the start of April, replaces the National Institute for Health Protection, which was itself established in August.

The new UKHSA is "to plan for, prevent, and respond to external health threats," according to a press release. In particular, the agency is to combine analytical and genomic capabilities with testing and contact tracing efforts.

"With the creation of the UKHSA, we have an unprecedented opportunity to build on the scientific and operational strength that has been developed, learn from the past, and further develop strong bonds with health protection leadership from global to local to ensure we are ready for the challenges of the future," Harries says in a statement.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.